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Abstract
Disease classification system increasingly incorporates information on pathogenic mechanisms to 
predict clinical outcomes and response to therapy and intervention. Technological advancements 
to interrogate omics (genomics, epigenomics, transcriptomics, proteomics, metabolomics, 
metagenomics, interactomics, etc.) provide widely-open opportunities in population-based 
research. Molecular pathological epidemiology (MPE) represents integrative science of molecular 
pathology and epidemiology. This unified paradigm requires multidisciplinary collaboration 
between pathology, epidemiology, biostatistics, bioinformatics, and computational biology. 
Integration of these fields enables better understanding of etiologic heterogeneity, disease 
continuum, causal inference, and the impact of environment, diet, lifestyle, host factors (including 
genetics and immunity), and their interactions on disease evolution. Hence, the Second 
International MPE Meeting was held in Boston in December 2014, with aims to: (1) develop 
conceptual and practical frameworks; (2) cultivate and expand opportunities; (3) address 
challenges; and (4) initiate the effort of specifying guidelines for MPE. The meeting mainly 
consisted of presentations of method developments and recent data in various malignant 
neoplasms and tumors (breast, prostate, ovarian and colorectal cancers, renal cell carcinoma, 
lymphoma, and leukemia), followed by open discussion sessions on challenges and future plans. 
In particular, we recognized need for efforts to further develop statistical methodologies. This 
meeting provided an unprecedented opportunity for interdisciplinary collaboration, consistent with 
the purposes of the BD2K (Big Data to Knowledge), GAME-ON (Genetic Associations and 
Mechanisms in Oncology), and Precision Medicine Initiatives of the U.S.A. National Institute of 
Health. The MPE Meeting Series can help advance transdisciplinary population science, and 
optimize training and education systems for 21st century medicine and public health.
Keywords
epidemiologic method; molecular pathologic epidemiology; personalized medicine; systems 
biology; translational epidemiology; unique disease principle
Introduction
A fundamental premise of epidemiology is that individuals with the same disease name have 
similar etiologies, and exhibit a similar disease evolution. These important principles 
(homogeneity and generalizability) constitute a firm basis to generate evidence for practice 
in clinical medicine and public health. Under this premise, the field of epidemiology has 
been established as the core scientific discipline of public health. Over recent decades, our 
improved knowledge of disease pathogenesis has transformed disease classification systems. 
It is also increasingly evident that pathogenic processes are fundamentally heterogeneous as 
indicated by the “unique disease principle”.[1, 2] The goal of using molecular disease 
signatures is to sub-classify disease to improve prediction of disease occurrence and 
progression for precision medicine and public health. With this evolution, the field of 
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molecular pathological epidemiology (MPE) has emerged as an integrative interdisciplinary 
field of molecular pathology and epidemiology.[3, 4] The concept of MPE has been well-
recognized in the recent literature.[5–60] Similar ideas and concepts have also been 
discussed.[61–64] At this point, most molecular pathology tests (hence, MPE studies) focus 
on neoplastic diseases, although the concepts and approaches of MPE can potentially 
transform epidemiology in virtually all disease areas including non-neoplastic conditions.[2, 
65] MPE can be one of the next steps of genome-wide association studies (GWAS; GWAS-
MPE approach), to decipher pathogenic roles of putative disease-causing genetic variants.[4] 
MPE has also contributed to the development of related paradigms and concepts, including 
the colorectal continuum model,[66, 67] the etiologic field effect model,[68] and the 
integrative lifecourse epidemiology-MPE.[69] The advancement and availability of 
molecular pathology technologies have opened enormous opportunities in population-based 
research, but also pose considerable challenges, including paucity of interdisciplinary 
experts and interdisciplinary education programs, and lack of research guidelines specific to 
MPE.
To advance integrative molecular and population-level health science and to address the 
unique research challenges specific to the field of MPE, experts in various fields including 
pathology, epidemiology, genomics, biostatistics, bioinformatics, and computational biology 
must work together. Along with the BD2K (Big Data to Knowledge), GAME-ON (Genetic 
Associations and Mechanisms in Oncology) and Precision Medicine Initiatives by the 
U.S.A. National Institute of Health (NIH), our effort of integrating these seemingly 
divergent fields can lead to a greater understanding of heterogeneity of the pathogenic 
process, and the impact of environmental, dietary, lifestyle, and host factors (including 
genetics and immunity), and their interactions on that process. Brainstorming and discussion 
fostered at a scientific meeting will lead to the development of new methodologies to 
address the unique research questions and challenges in this emerging field.
Thus, the First International MPE Meeting (led by Dr. Shuji Ogino) was held as a closed 
meeting at the Harvard School of Public Health in Boston on April 24, 2013, where 10 
investigators gathered. Based on the success and productivity of this small, closed meeting, 
plans were made for a larger international MPE meeting.
On December 4–5, 2014, the Second International Molecular Pathological Epidemiology 
(MPE) Meeting, open to the worldwide research community, was held at the Dana-Farber 
Cancer Institute (Boston, MA). The conference handbook is available as Supplementary 
Material. There were a total of approximately 150 attendees from 16 countries. The specific 
aims of this meeting were to: 1) develop a conceptual and practical framework for MPE; 2) 
cultivate and expand opportunities; 3) address challenges in MPE; and 4) initiate the effort 
of designing guidelines for MPE research (“STROBE-MPE”), as first proposed in 2012.[70, 
71] Making consensus guidelines that will improve study reporting is one of well-
established strategies to build a field and enhance its contributions, as evidenced by the 
development of the guidelines for clinical trials.[72, 73]
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The meeting started with the overview session (moderated by Dr. Hongmei Nan). Dr. Ogino 
presented an introductory lecture on MPE, emphasizing its strengths, opportunities, and 
challenges. MPE research has shown that smoking and obesity are risk factors for different 
subtypes [microsatellite instability (MSI) and non-MSI subtypes, respectively] of colorectal 
cancer,[11, 33, 74–84] which is a single entity in conventional epidemiology. This paradigm 
shift is important in cancer prevention. For example, colonoscopy may be less effective for 
reducing risk of MSI-high colorectal cancers than for non-MSI cancers,[85, 86] and hence, 
smokers who are at risk of MSI-high colorectal cancer may need to have different screening 
strategies. With the simplest scenario of a binary disease subtypes (e.g., A and B), to show 
etiologic heterogeneity, three hypotheses must be evaluated: (1) the exposure relates to 
subtype A; (2) the exposure relates to subtype B; and (3) there is heterogeneity between the 
“(1)” and “(2)” relationships. Notably, many molecular biomarkers are not simple binary 
measures, and disease can be classified by multiple markers into multiple subtypes. Thus, 
there exists a need to develop new statistical methods to address etiologic heterogeneity in 
many different scenarios. As open opportunities, molecular pathology tests have become 
routine clinical practice in many parts of the world, and we can potentially utilize 
accumulating disease molecular data.[87]
Dr. Edward Giovannucci presented a lecture on the utility of the MPE approach to enhance 
causality in epidemiology. One of the strongest criteria used in observational studies to 
assess causality is the magnitude of the relative risk. Not uncommonly, a risk factor may be 
associated only with a minority subtype of a given cancer. In that case, the relative risk for 
all subtypes combined as a singular disease is diluted and may be imperceptible. A recent 
example is the association of vegetable intake and ESR1 (estrogen receptor 1, ER)-negative 
breast cancer. In a large pooling study,[88] high intake of vegetables was associated with an 
18% lower risk of ESR1-negative breast cancer. As ESR1-negative breast cancers represent 
only approximately 20% of all breast cancer, no discernible association was apparent for 
total breast cancer. A similar example is seen for smoking in relation to colorectal cancer 
risk. Smoking is associated with a two-fold risk for CIMP-high (or MSI-high) colorectal 
cancer, whereas a null association is observed for non-CIMP (or non-MSI) subtypes.[74–76] 
As CIMP-high colorectal cancer accounts for 15% to 20% of the total, the association 
between smoking and total colorectal cancer has been weak-to-modest. These two examples 
illustrate that important etiologic factors could easily be missed when cancer heterogeneity 
is not taken into account.
Colorectal and breast cancers
As the two cancers that have been most widely studied using MPE, a session was devoted to 
research on colorectal and breast cancers (moderated by Dr. Kana Wu). With respect to 
colorectal cancer,[89–92] Dr. Peter Campbell presented a lecture summarizing MPE 
research in the area of obesity. Energy balance and metabolism have been implicated in 
cancer evolution.[93–98] Recently, MPE studies have investigated whether the association 
of risk factors (including high body mass index, BMI) with colorectal cancer differs by 
tumor molecular features. While high BMI is a consistent and convincing risk factor for 
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colorectal cancer overall (relative risks in the range of 1.3 to 1.5 are common for an obese 
BMI relative to a normal BMI), MPE studies have overall suggested that the associations are 
stronger for, or even restricted to, non-MSI colorectal cancer (relative risks up to around 2 
are common for an obese BMI relative to a normal BMI).[11, 33, 82–84] Other recent 
studies have shown that these results might be corroborated with expression status of FASN,
[99] which has been associated with MSI-high in colorectal cancer.[100] These data also 
indicate the existence of molecular confounding in MPE, and a need for new methodologies 
to disentangle correlated molecular biomarkers.
Dr. Andrew Chan presented a lecture on MPE research into the relationship between aspirin 
use and colorectal cancer. Consistent experimental and epidemiologic evidence indicates 
that aspirin reduces colorectal cancer risk.[18, 101, 102] Data also support an association 
between aspirin use and improved outcomes among colorectal cancer survivors. 
Nonetheless, current clinical guidelines recommend against the routine use of aspirin to 
prevent colorectal cancer in individuals at average risk largely due to concerns about its 
potential gastrointestinal toxicity. His group has conducted several MPE studies [103–109] 
to shed light on the mechanistic basis of aspirin’s anti-cancer effect, and to identify tumor, 
germline, and plasma biomarkers for potential risk stratification to more effectively target 
aspirin chemoprevention and treatment. In particular, aspirin use appears to be strongly 
associated with lower mortality among patients with PIK3CA-mutated colorectal cancer.
[106, 110] Moreover, recent results from secondary analyses of randomized controlled trials 
of aspirin for cardiovascular prevention has shown that aspirin’s effects may extend to 
benefits for cancers beyond the colon, persuasively making the case for a broader role for 
aspirin in cancer prevention. In summary, evidence supports a role for aspirin in the 
prevention and treatment of colorectal cancer, and there will be novel strategies for 
molecular risk stratification.
With respect to breast cancer, Dr. Montserrat Garcia-Closas presented research into this 
molecularly-heterogeneous disease. The breast microenvironment and etiologic factors for 
breast cancer change throughout the life course, in step with hormonal changes during 
puberty, pregnancy, lactation, and peri-menopausal periods. Although there are many well-
established risk factors for breast cancer overall, increasing evidence indicates that such risk 
factors differ in the magnitude of their impact according to common somatic attributes. In 
particular, several reproductive risk factors demonstrate different associations with breast 
cancer subtypes based on their expression of hormone receptors, such as ESR1 (estrogen 
receptor 1). Recently, GWAS successfully identified many risk variants for breast cancer, 
and efforts have started to clarify specific associations of risk variants with major and minor 
subtypes of the disease. A recent study successfully identified risk variants for the ESR1-
negative subtype,[111] which had not been identified as risk alleles in GWAS of overall 
breast cancer. This attests to utility of the MPE approach to discover hidden etiologic factors 
which have not been uncovered by traditional genetic epidemiology.
Dr. Rulla Tamimi further expanded on the MPE of breast cancer, describing multiple disease 
subtypes. These subtypes vary in tumor gene expression and phenotype, and are most 
commonly grouped into four major subtypes: luminal A-like, luminal B-like, ERBB2 
(HER2)-positive, and triple-negative (or basal-like). Reproductive and hormonal factors 
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(e.g., younger age at menarche, older age at first child birth, having fewer children, older age 
at menopause, and use of hormonal therapy) have been associated with increased risk of 
luminal A-like breast cancer and, less consistently, luminal B-like cancer.[112, 113] Family 
history of breast cancer is the only established risk factor for the ERBB2-positive subtype.
[114, 115] Younger age at menarche is positively associated with triple-negative breast 
cancer, while breastfeeding appears to be inversely associated with this disease subtype.
[112, 113] Future studies focusing on novel risk factors with consideration for disease 
heterogeneity may help identify risk factors for less common and more aggressive types of 
breast cancer. Such studies of less common subtypes will require pooling of data across 
studies, as individual studies are underpowered to evaluate etiologic heterogeneity.
Special session: hot topics
A special session was held to highlight two emerging hot topics relevant to MPE (moderated 
by Dr. Ogino). Dr. Matthew Meyerson, a pioneer in cancer genomics, presented a lecture on 
cancer tissue microbiome analysis. He developed PathSeq which is a computational 
subtraction method to detect pathogen sequences from next generation sequencing data,
[116] and applied this approach in the discovery of Fusobacterium species, in particular 
Fusobacterium nucleatum, in colorectal cancer tissue.[117] The amount of Fusobacterium 
nucleatum has been shown to be higher in colorectal cancer tissue compared to adjacent 
normal colon, and is associated with specific molecular attributes in colorectal cancer tissue: 
MSI-high and CIMP-high status.[118, 119] Fusobacterium nucleatum has also been shown 
to promote tumorigenesis in a mouse model of colorectal cancer, potentially by inhibiting 
anti-tumor adaptive T-cell immune response.[120] Thus, tumor tissue microbiome analyses 
can reveal potential pathogens which can represent both epidemiologic exposures and tumor 
molecular signatures, and will provide enormous opportunities in MPE research.
Dr. Adam Bass, co-chair for both gastric cancer and esophageal cancer projects in The 
Cancer Genome Atlas (TCGA), presented a lecture on updates of the gastric TCGA project.
[121] There are four major molecular subtypes of gastric carcinoma: EB virus (EBV)-
associated, MSI (hypermutator), genomically stable (commonly diffuse histopathology 
subtype), and chromosomal instability subtypes. Biogeographical differences in tumors 
within the stomach, as well as histopathological diversity, have also been identified through 
TCGA and were described. Features of EBV-associated gastric cancer include frequent 
PIK3CA mutation and amplification and up-regulation of CD274 (PD-L1) and PDCD1LG2 
(PD-L2), which are immune checkpoint ligands and can be targets of immunotherapy. These 
findings support the importance of molecular classification for gastric cancers in clinical and 
epidemiologic research to identify specific risk factors and therapeutic targets. In summary, 
TCGA findings are useful in designing large-scale MPE studies on gastric cancers.
MPE pooling projects
Considering the unique disease (or tumor) principle, it is necessary to examine a large 
number of cases, most likely by designing pooling consortium projects; thus, a session was 
devoted to existing pooling projects that have facilitated MPE research (moderated by Dr. 
Liam Murray). Dr. Lindsay Morton described the InterLymph Consortium, a pooling project 
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on the epidemiology of lymphomas. InterLymph was initiated in 2001 and presently 
includes 20 studies with 17,500 cases of non-Hodgkin lymphomas (NHLs) and 23,000 
controls.[122] Despite the challenge of harmonizing data across the different studies, MPE 
research through InterLymph has demonstrated epidemiologic similarities and differences 
across NHL subtypes. For example, autoimmune diseases, hepatitis and alcohol are risk 
factors for T-cell NHLs, marginal zone lymphoma, Burkitt lymphoma, diffuse large B-cell 
lymphoma, while genetic variants (identified by GWAS) are the only established risk factors 
for chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, and 
mantle cell lymphoma. As InterLymph matures, this resource can generate a wealth of MPE 
data.
Dr. Ulrike Peters presented a lecture on the Genetics and Epidemiology of Colorectal 
Cancer Consortium (GECCO). GECCO was first funded by the NIH as a GWAS consortium 
to characterize genetic susceptibilities to colorectal cancer and modifying effects of gene-by-
environment interaction. The newest GECCO U01 project, “Molecular Pathological 
Epidemiology of Colorectal Cancer”, was recently successfully renewed in 2014. The 
renewal U01 grant has MPE projects on various exposures and standard tumor molecular 
biomarkers, including mutations in KRAS, BRAF, and PIK3CA, and MSI and CIMP statuses. 
The aims of this ongoing collaborative effort also include analyses of over 4000 colorectal 
cancers by targeted sequencing of 200 driver genes. As most of the driver genes are only 
mutated in a small fraction of the cases (most are expected to be mutated in <5% of cases), it 
is critical to group mutated genes in meaningful ways, such as mutated pathways to ensure 
sufficient statistical power for subtype analysis. Furthermore, deep targeted sequencing will 
allow identifying mutations in small fractions of the tumor, to investigate tumor 
heterogeneity. These novel data will require novel statistical analytical approaches.
The lectures were followed by a panel discussion (by Drs. Lindsay Morton, Ulrike Peters, 
Stephanie Smith-Warner, and Piet van den Brandt). The panelists emphasized the 
importance of harmonization of tumor molecular data in MPE pooling projects. Dr. Piet van 
den Brandt presented results on pooling of MPE data from two prospective cohort studies: 
the Netherlands Cohort Study and the Melbourne Collaborative Cohort Study. These 
collaborative projects have shown consistent data with improved robustness of findings on 
anthropometric factors and colorectal cancer risk according to tumor status of MSI and 
BRAF mutation.[11]
Statistical opportunities and challenges in MPE
Methodologic issues and statistical challenges in MPE were highlighted in a session 
(moderated by Dr. Donna Spiegelman). Dr. Colin Begg presented statistical methods to 
address etiologic heterogeneity. His talk focused particularly on the discovery of 
etiologically distinct sub-types, a task that is conceptually and computationally challenging 
because of the complexity of the somatic portraits of individual tumors and of the 
corresponding profiles of risk factors. To permit an organized framework for investigating 
etiological heterogeneity he proposed a scalar statistical measure that captures quantitatively 
the degree of heterogeneity exhibited by any candidate set of tumor sub-types. This 
facilitates the exploration of countless sub-typing options to identify the set or sets that 
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possess the greatest evidence of heterogeneity.[64] He also explained the unique insights 
that can be obtained by investigating and correlating the mutational profiles of double 
primary malignancies,[123] and illustrated the concepts using studies of breast cancer, 
melanoma and kidney cancer.
Dr. Molin Wang described statistical methods to study etiologic heterogeneity using 
categorical, ordinal and multi-marker classifiers. Methods were reviewed for scenarios 
where disease subtypes are categorical in cohort studies, matched and unmatched case-
control studies, and case-case study designs. New methods were discussed for ordinal 
disease subtypes. For analyzing studies with disease subtypes defined by multiple 
categorical and/or ordinal markers, Dr. Wang presented a meta-regression method which 
uses existing statistical software for the mixed model analysis.[124] That method can be 
used to test for heterogeneity across multiple disease subtypes classified by multiple 
markers, to assess whether the exposure-subtype associations are different across subtypes 
defined by one marker while controlling for other markers, and to evaluate whether the 
difference in exposure-subtype association across subtypes defined by one marker depends 
on any other marker.
Dr. Nilanjan Chatterjee presented on the development of methodologies to address etiologic 
heterogeneity,[125, 126] including one novel method: Association Analysis based on Subset 
(ASSET). ASSET was described as a means for detecting disease-exposure associations in 
the presence of heterogeneous subtypes. The method explores all possible subsets of disease 
subtypes and asses significance of the association for the best subset after accounting for 
multiple-testing adjustment using an efficient procedure. The method has robust power 
compared to alternative approaches for detecting overall association in the presence of 
etiologic heterogeneity and produces readily interpretable results through identification of 
the disease types that drive a given association. Examples were shown from a recent 
application of the method to cross-cancer analysis of GWAS data.
Dr. Bernard Rosner described statistical methods to address etiologic heterogeneity and 
disentangle molecular confounding by multiple correlated biomarkers. The correlation of 
markers makes it difficult to ascribe interaction effects of a risk factor with a specific marker 
without considering other markers. In addition, there are often tumor markers with missing 
data for some subjects. To resolve this, Dr. Rosner discussed a two-stage regression 
approach.[127] At a first stage, markers are cross-classified and the Beta coefficient for a 
given risk factor is obtained for the outcome defined by each combination of markers. At a 
second stage, a regression is performed of the regression coefficients from the first stage on 
a vector of tumor characteristics. This yields a test of heterogeneity of effects of a risk factor 
by a specific marker while controlling for the effects of other markers and an associated 
estimate of effect characterized by an “adjusted hazard ratio.” Dr. Rosner also compared 
different methods for handling missing marker data including complete case, missing 
indicator, inverse probability weighting, and multiple imputation methods. Additional 
simulation studies are needed to compare these methods for handling missing marker data.
Dr. Eric Tchetgen Tchetgen presented a lecture on unique methodological considerations in 
the face of outcome heterogeneity. He first discussed the so-called obesity paradox. In an 
Ogino et al. Page 8













example of this paradox, obesity is associated with better clinical outcomes among patients 
with a disease for which obesity has been shown to be a risk factor. This paradox can be 
explained by considering heterogeneity of disease. He then focused on the situations in 
which a risk factor is important for some subtypes but not for others. He discussed the 
possible underestimation of association if the standard nominal polytomous logistic 
regression models are used when the disease is not rare. To avoid underestimation, he 
suggested using the subtype-specific logistic regression model for each subtype, with a 
constraint that the sum of the subtype-specific probability is one.
High dimensional data and cellular heterogeneity
Reflecting the increasingly complex and high-dimensional nature of MPE data, we had a 
session on bioinformatics and computational pathology (moderated by Dr. Reiko Nishihara). 
Dr. Rafael Irizarry presented a lecture on cellular heterogeneity, batch effects and 
confounding. Technical artifacts and measurement errors can become serious confounders 
which occur due to the difference in tissue collection design, laboratory conditions, etc. 
among samples and batches of collection and processing.[128] These factors can easily lead 
to spurious findings which have nothing to do with biological implications. Variability in 
cellular composition can be another source of serious confounding, for example, in 
epigenetic research on specimens with mixture of different cell types.[129] An example of 
data was presented from a study to identify DNA methylation profiles using peripheral 
blood cells, which consist of many different cell types in varying proportions among 
individuals and among different time points even within one individual. Appropriate 
statistical and experimental solutions should be considered to adjust for batch effects and to 
estimate the relative proportion of cell types in tissue or blood specimens.
Dr. Karl Kelsey described the use of epigenetic markers to differentiate and quantify 
specific cell types in a cell mixture. The epigenome, including DNA methylation, is 
responsible for the overall control of gene expression and can be altered by the environment. 
DNA methylation is associated both with lineage specific differentiation in development and 
somatic differentiation of stem cells throughout life. Epigenetic plasticity might contribute 
to numerous environmentally-associated adverse health outcomes. The epidemiologic 
literature now includes numerous reports of highly significant associations of both 
environmental exposures and disease states with changes in the DNA methylation profile of 
blood cells. In assessing the nature of these associations, Dr. Kelsey noted consistent 
observations indicating that the vast majority of the variation can be explained by 
accounting for shifts in leukocyte subtypes.[130] Dr. Kelsey showed how it can be exploited 
in epidemiologic studies (amenable to use with archived blood samples), providing a 
window into the assessment of an individual immune profile.
Dr. Andrew Beck presented on computational pathology to address disease heterogeneity. 
Inter-tumoral heterogeneity is a major challenge in MPE, and there is a need for the 
development of new computational and statistical approaches for significance testing for 
Omics analyses in large, heterogeneous patient populations. Dr. Beck described two 
computational methods he recently developed to address this challenge. The first approach, 
Significance Analysis of Prognostic Signatures (SAPS),[131] is a method for identifying 
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prognostic gene sets that: 1) stratify patients into groups that show significant survival 
differences; 2) perform significantly better than random gene-sets at predicting patient 
survival; and 3) are enriched for prognostic genes. He also described his recently developed 
Earth Movers Distance Omics (EMDomics) method, which uses the Earth Movers Distance 
to identify genes that are differentially expressed between heterogeneous classes of samples. 
Using both simulations and real biological data, Dr. Beck has shown that EMDomics 
outperforms competing approaches for the identification of genes differentially expressed 
between heterogeneous groups. The SAPS and EMDomics R packages should be useful for 
prognostic studies and two-class significance testing (respectively) in MPE studies.
Pathology and pathogenesis
Understanding of disease pathology and pathogenesis is central to MPE,[61] and was the 
focus of another session (moderated by Dr. Paul Lochhead). Dr. Mark Sherman and Dr. 
Melissa Troester presented related lectures on pathogenic insights into breast cancer 
development, with a focus on research into terminal duct lobular units (TDLUs). The 
morphological and molecular characteristics of “normal appearing” tissues that harbor 
potentially carcinogenic alterations, collectively referred to herein as “molecular histology,
[132] undergo changes over the life course. Environmental exposures interact with normal 
tissues to produce physiological functions, benign alterations, and in some instances, 
carcinogenesis. A similar concept has been recently consolidated as “etiologic field effect”.
[68] Studying the transition from normal to the earliest identifiable preneoplastic changes 
represents an important opportunity to better understand the underlying biology of risk. 
TDLUs are the structures of the breast that produce milk and also give rise to breast cancer 
precursors. TDLUs undergo a range of morphological changes related to puberty, 
pregnancy, lactation, aging, and menopause,[133, 134] and can also accompany altered 
molecular histology and a change in mammographic density. Studies have found that, 
among women with benign breast biopsy, reduced levels of TDLU involution in the 
surrounding normal breast are associated with breast cancer risk.[135, 136] Thus, the topic 
of “molecular histology” and MPE are linked, and cancer precursor lesions can be used as 
an intermediary phenotype to examine carcinogenic processes in MPE studies.[137] Studies 
have shown that the dominant expression subtypes of normal breast tissue are highly 
correlated with both mammographic density and histology, suggesting that such expression 
patterns could follow patterns of risk, and moreover, that some of the pathways driving 
histological change could be identified in gene expression studies.[138, 139] Further 
research is needed to understand key associations between normal appearing breast 
epithelium, with or without specific molecular alterations, and breast cancer, including: 1) 
possible short-term increased risk following a live birth; 2) the long-term protection of 
pregnancy for late onset cancers (mainly hormone receptor positive); 3) the possible 
relationship of giving birth and increased risk of basal-like breast cancers and 4) the 
suggested protective effect of breastfeeding, especially for basal-like cancer.[140] In 
tandem, mechanistic studies conducted in animal models and based on insights from gene 
expression profiling may deepen insight into the molecular processes that drive TDLU 
development, involution and carcinogenesis, and may suggest interventions that can modify 
risk.
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MPE of various cancers
Day two of the Meeting began with a session devoted to various cancers not covered in 
discussions from the first day (moderated by Dr. Amanda Phipps). Dr. van den Brandt 
presented research into the MPE of renal cell carcinoma with respect to heterogeneity in 
both etiology and prognosis. Risk factors associated with clear cell renal cell carcinoma 
appear to differ by VHL mutation status. MPE research on renal cell carcinoma has also 
given clues to the so-called obesity paradox.[141] The obesity paradox refers to the fact that, 
while obesity is a risk factor for a certain disease (such as renal cell carcinoma), obesity is 
associated with better clinical outcome among some individuals with the disease. Renal cell 
carcinomas in obese individuals are more likely tumors with low-level FASN expression, 
which appear to be an indolent subtype associated with better outcome.
Dr. Lorelei Mucci described her MPE research into prostate cancer. Prostate cancer follows 
a disease model where premalignant and malignant tumors can be detected by screening or 
symptomatology, and benign and malignant tumors form histopathological and clinical 
spectra. Therefore, unlike with many other cancers, prostate cancer cases are often sub-
classified into lethal and non-lethal subtypes based on clinical behavior.[142] Dr. Mucci 
presented data from the Health Professionals Follow-up Study and Physicians’ Health Study 
on obesity and lethal prostate cancer.[143] Whole genome mRNA profiling has been used to 
conduct gene expression profiling of prostate cancers in these cohorts, and genes related to 
chromatin remodeling pathway and RNA processing and metabolism pathway have been 
shown to be differentially expressed in lethal vs. non-lethal subtypes. Molecular signatures 
for aggressive versus indolent cancers may be useful in clinical management of prostate 
cancer.
Dr. Shelley Tworoger presented a lecture on the MPE of ovarian cancer. As with other 
cancers under discussion, ovarian cancer is a group of heterogeneous diseases, and risk 
factor associations appear to differ by tumor subtype.[144, 145] Because there is an issue of 
limited statistical power in each subtype in any single study, consortia are needed to fully 
explore subtype-specific associations with exposures and clinical outcomes. In ovarian 
cancer, meaningful metrics to categorize disease can be obtained from pathology reports 
(e.g., histopathologic features) and other data sources (e.g., death information). Considering 
multiple metrics of disease heterogeneity (e.g., histopathology, molecular pathology, and 
time to death) can provide a deeper insight into etiology and help target prevention 
recommendations to the most aggressive forms of ovarian cancer.
Open discussion sessions
To maximize the utility of the International MPE Meeting, and to augment the invited 
lecture sessions, emphasis was placed on open discussion sessions where experts in diverse 
disciplines shared their perspectives and brainstormed ideas for new directions, priorities, 
and collaborations. We systematically discussed a number of important opportunities and 
issues in MPE, as described in the following sections.
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Interdisciplinary education (moderated by Drs. Troester and Mucci)
Paucity of interdisciplinary education and training has been a challenge in MPE. Because 
molecular pathology has become pervasive in all areas in medicine and public health, 
doctoral competencies for epidemiologists in terms of adequate knowledge and skills on 
both pathology and epidemiology should be defined. In particular, knowledge in multiple 
areas including biology, physiology, pathology, clinical medicine, statistics, and 
bioinformatics is important. As technologies continue to advance, skills to update own 
knowledge and competencies are essential. Meeting attendees suggested possible workshops 
for interested students and junior investigators, and the development of online resources. 
Attendees also emphasized the importance of transdisciplinary collaborations in facilitating 
the interdisciplinary training so important to MPE.
Study design and statistical methods (moderated by Drs. Wang and Aya 
Kuchiba)
Various topics related to the statistics of MPE research were discussed, especially themes 
that were not adequately discussed by the lectures (e.g., including missing data and 
measurement error in disease subtyping biomarkers). Challenges to the analysis of high-
dimensional molecular marker data and rare subtypes were highlighted as research priorities. 
Other challenges discussed included various sources of bias caused by pre-analytic, analytic 
and post-analytic processes in pathology procedures and data; concerns surrounding 
multiple hypothesis testing due to the evaluation of multiple exposures and outcomes 
(disease subtypes); timing and latency issues with respect to exposures and molecular events 
in cells and tissues. In summary, meeting attendees expressed the importance of addressing 
challenges in study design and statistics, in order to fully exploit enormous opportunities 
which await investigators in MPE.
Routine collection of molecular pathology data (moderated by Drs. Beck 
and Sherman)
Moderators highlighted routine pathology procedures from tissue handling to molecular data 
generation. Tissue life-cycle includes sampling, fixation, processing, assay, scoring/
interpretation, database, and data analyses. The availability of tissues for assay is limited by 
clinical requirements. Compared to disease tissue (e.g., cancer tissue) which is collected for 
pathology diagnosis and patient management, normal (or pre-disease) tissue is not easy to 
obtain from individuals. To resolve this issue, ultimately, in vivo pathology technologies will 
become available for in vivo monitoring of pathologic processes, and transform all areas of 
population health sciences. Intra-tumor heterogeneity was also discussed as an unresolved 
issue in epidemiology. It is an active area of investigation, and evidence is accumulating for 
its role in resistance of cancer to various types of drugs including targeted therapeutic 
agents. In summary, there are widely open opportunities in utilization of tissue resources in 
epidemiology and population health sciences.
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Pooling MPE data (moderated by Drs. Morton, Peters, van den Brandt, and 
Smith-Warner)
Continuing conversations initiated in earlier sessions, several investigators with experience 
in pooling projects led a discussion on the challenges (and advantages) of such collaborative 
efforts. MPE inherently deals with disease subtypes which have smaller sample sizes than an 
overall disease sample. Therefore, pooling projects are essential in MPE to increase sample 
sizes, and examine generalizability and effect modification of exposure – disease subtype 
associations. Challenges include standardization and reproducibility of biomarker 
measurements, and funding which is necessary to conduct centralized laboratory tests. 
Ongoing MPE pooling projects such as InterLymph and GECCO will continue to provide 
guidance in other consortium initiatives.
Research guideline development (STROBE-MPE) (moderated by Dr. Ogino)
Dr. Ogino presented introductory slides on background of the STROBE (Strengthening the 
Reporting of Observational Studies in Epidemiology) initiative,[146, 147] and suggested the 
need for MPE guidelines. There is an extension of STROBE in molecular epidemiology 
(STROBE-ME) Guidelines;[148, 149] however the STROBE-ME guideline does not 
address many of the challenges in MPE which were discussed in the Meeting. Thus, the 
“STROBE-MPE” guideline project has been proposed,[70, 71] and the STROBE group has 
agreed with the MPE group to have Dr. Matthias Egger as a liaison for the STROBE-MPE 
project. It was discussed whether a recommendation (rather than a guideline) by an expert 
panel might serve for the research community. At this time, as a relatively young field, MPE 
researcher needs to accumulate more data, and investigators need to develop new 
methodologies to address etiologic heterogeneity. Once made, a recommendation or 
guideline must be updated to keep up technological advancements.
Possible collaboration projects (moderated by Drs. Giovannucci and Wang)
The purpose of this session was to conduct brainstorming of experts in diverse disciplines. 
Since molecular pathology tests have become routine clinical practice, molecular biomarker 
data are accumulating in hospitals. Routine collection of such data may be very useful. 
Collaboration can be possible for molecular pathological epidemiologists with researchers in 
areas such as causal inference, comparative effectiveness research and health 
communication. Collaboration among statisticians can be effective for solving statistical 
issues. Possibly, a consortium can form to ensure the external validity and reproducibility of 
new statistical methods.
Relationships with other societies (moderated by Drs. Murray, Campbell, 
and van den Brandt)
To continue the International MPE Meeting Series, attendees discussed the worth of 
synergizing with activities of other well-established societies, including those in 
epidemiology, pathology, laboratory medicine, statistics, cancer research, oncology and 
other clinical disciplines. Since routine molecular analyses on disease are most commonly 
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conducted on cancer and neoplastic diseases, much MPE research currently focuses on 
neoplastic diseases. Though many societies were discussed, in particular, international 
societies have broad influence on global health, and we can consider those as potential 
candidate societies to which we can relate; those include American Association for Cancer 
Research (AACR), Society for Epidemiologic Research (SER), American College of 
Epidemiology (ACE), International Epidemiological Association (IEA), United States and 
Canadian Academy of Pathology (USCAP), American Society for Investigative Pathology 
(ASIP), and Association for Molecular Pathology (AMP).
Planning the Third International MPE Meeting (moderated by Drs. Phipps, 
Ogino, and Elizabeth Poole)
Based on comments offered by Meeting attendees, it was suggested that the International 
MPE Meeting Series continue to be an interactive forum of combining succinct lectures and 
discussion sessions. Possibilities of settings dates close to another scientific society or 
consortium meeting were discussed, as were possible meeting themes, location, and issues 
of timing, with the goal of attracting diverse groups of researchers including pathologists, 
epidemiologists, biostatisticians and bioinformaticians. It was suggested that incorporating 
hands-on workshops may increase the value of the meeting. Attendees tentatively agreed 
that the Third International Meeting be held in Boston in Spring 2016. In the future, the 
International MPE Meeting may be held in other cities.
Meeting abstracts, posters, and awards
Rapid dissemination of new research findings and knowledge is an important purpose of our 
meeting. Hence, a fraction of participants submitted abstracts, and made posters for 
distribution at the meeting. We also projected poster slides during each break time. For 
presenters who applied for an award, poster referees discussed findings with them and 
scored merits of each poster presentation. Awards were made to recognize the efforts of 
junior scientists in conducting high quality interdisciplinary MPE research, and to facilitate 
further transdisciplinary integration. Referees selected the following awardees for their 
outstanding abstract and poster presentations: Molecular Pathological Epidemiology Rising 
Investigator Award (junior faculty) to Drs. Aditi Hazra and Xuehong Zhang; Molecular 
Pathological Epidemiology Trainee Award (post-doctoral fellow or other trainee) to Drs. 
Mingyang Song and Atsuhiro Masuda. We plan to continue to provide these opportunities at 
The International MPE Meeting Series.
Meeting evaluation by participants
Participants filled out an evaluation form to assess quality of the Second International MPE 
Meeting with respect to the overall program, topics, speakers, discussion sessions, and 
logistics. On a scale of 1 (poor) to 5 (excellent), average scores were 4.5 for the overall 
program, 4.7 for the speakers and discussions, and 4.3 for logistics, indicating overall 
success of the meeting. We also provided the participants with a write-in space for 
comments. Reflecting attendee satisfaction with the quality of the Meeting, we herein quote 
some examples: “This is a great meeting”; “Really enjoyed the built-in discussions”; 
Ogino et al. Page 14













“Timing well coordinated”; “It was great to have a session on statistical analyses”; “Many 
areas well explored.” In terms of room for improvement in future meetings, attendees 
commented as follows: “Bring more pathologists and touch more on bioinformatics”; 
“Would be good to provide tea as well and provided food for all”; “There is no capacity for 
big posters.” In summary, evaluations and feedback by the participants indicated their 
general satisfaction and enthusiasm, and it is the basis for our plan to organize and have the 
Third International MPE Meeting in Spring 2016.
Conclusions
The Second International MPE Meeting brought together experts in divergent fields who are 
working on big data of exposures, molecular pathology of disease, and disease evolution in 
population-based settings. Brainstorming and discussions fostered by the meeting are and 
will be helpful for the meeting participants in pursuit of this relatively young field. In the 
foreseeable future, molecular pathology tests will become prevalent in many different 
diseases, and make disease molecular data widely available. Because heterogeneity of 
pathogenic processes is an undisputable phenomenon, medical and health research must 
consider this fundamental nature of disease, along with the disease continuum theory.[150] 
Thus, the MPE paradigm should become ubiquitous in all fields of population health 
sciences. We also recognize efforts to further develop statistical methodologies are needed. 
Given advancements of various omics technologies to analyze diseases, new opportunities 
are widely open to study virtually any disease. We look forward to continuing brainstorming 
and discussions at the Third International MPE Meeting in spring of 2016.
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